Abstract
The use of multigene panels for the assessment of cancer susceptibility is expanding rapidly in clinical practice, particularly in the USA, despite concerns regarding the uncertain clinical validity for some gene variants and the uncertain clinical utility of most multigene panels. So-called 'moderate-penetrance' gene mutations associated with cancer susceptibility are identified in approximately 2–5% of individuals referred for clinical testing; some of these mutations are potentially actionable. Nevertheless, the appropriate management of individuals harbouring such moderate-penetrance genetic variants is unclear. The cancer risks associated with mutations in moderate-penetrance genes are lower and different than those reported for high-penetrance gene mutations (such as mutations in BRCA1 and BRCA2, and those associated with Lynch syndrome). The extrapolation of guidelines for the management of individuals with high-penetrance variants of cancer-susceptibility genes to the clinical care of patients with moderate-penetrance gene mutations could result in substantial harm. Thus, we provide a framework for clinical decision-making pending the development of a sufficient evidence base to document the clinical utility of the interventions for individuals with inherited moderate-penetrance gene mutations associated with an increased risk of cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Knudson, A. G. Jr Mutation and cancer: statistical study of retinoblastoma. Proc. Natl Acad. Sci. USA 68, 820–823 (1971).
Domchek, S. M. et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304, 967–975 (2010).
Easton, D. F. et al. Gene-panel sequencing and the prediction of breast-cancer risk. N. Engl. J. Med. 372, 2243–2257 (2015).
Offit, K. & Garber, J. E. Time to check CHEK2 in families with breast cancer? J. Clin. Oncol. 26, 519–520 (2008).
Robson, M. CHEK2, breast cancer, and the understanding of clinical utility. Clin. Genet. 78, 8–10 (2010).
Kurian, A. W. et al. Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. J. Clin. Oncol. 32, 2001–2009 (2014).
Couch, F. J. et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J. Clin. Oncol. 33, 304–311 (2015).
Cragun, D. et al. Panel-based testing for inherited colorectal cancer: a descriptive study of clinical testing performed by a US laboratory. Clin. Genet. 86, 510–520 (2014).
LaDuca, H. et al. Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients. Genet. Med. 16, 830–837 (2014).
Lincoln, S. E. et al. A systematic comparison of traditional and multigene panel testing for hereditary breast and ovarian cancer genes in more than 1000 patients. J. Mol. Diagn. 17, 533–544 (2015).
Maxwell, K. N. et al. Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1/2-negative patients with early-onset breast cancer. Genet. Med. 17, 630–638 (2015).
Minion, L. E. et al. Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2. Gynecol. Oncol. 137, 86–92 (2015).
Tung, N. et al. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Cancer 121, 25–33 (2015).
Walsh, T. et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc. Natl Acad. Sci. USA 108, 18032–18037 (2011).
Yurgelun, M. B. et al. Identification of a variety of mutations in cancer predisposition genes in patients with suspected Lynch syndrome. Gastroenterology 149, 604–613 e20 (2015).
Domchek, S. M., Bradbury, A., Garber, J. E., Offit, K. & Robson, M. E. Multiplex genetic testing for cancer susceptibility: out on the high wire without a net? J. Clin. Oncol. 31, 1267–1270 (2013).
Desmond, A. et al. Clinical actionability of multigene panel testing for hereditary breast and ovarian cancer risk assessment. JAMA Oncol. 1, 943–951 (2015).
Rosenthal, E. T. et al. Outcomes of clinical testing for 50,000 patients utilizing a panel of 25 genes associated with increased risk for breast, ovarian, colorectal, endometrial, gastric, pancreatic, melanoma, and prostate cancers [abstract]. J. Clin. Oncol. 33, 1515 (2015).
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: genetic/familial high-risk assessment: breast and ovarian. http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf (2016).
Easton, D. F. et al. No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing. J. Med. Genet. http://dx.doi.org/10.1136/jmedgenet-2015-103529 (2016).
Loveday, C. et al. Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat. Genet. 43, 879–882 (2011).
Loveday, C. et al. Germline RAD51C mutations confer susceptibility to ovarian cancer. Nat. Genet. 44, 475–476; author reply 476 (2012).
Rafnar, T. et al. Mutations in BRIP1 confer high risk of ovarian cancer. Nat. Genet. 43, 1104–1107 (2011).
Cybulski, C. et al. Germline RECQL mutations are associated with breast cancer susceptibility. Nat. Genet. 47, 643–646 (2015).
Dreijerink, K. M., Goudet, P., Burgess, J. R. & Valk, G. D. & International Breast Cancer in MEN1 Study Group. Breast-cancer predisposition in multiple endocrine neoplasia type 1. N. Engl. J. Med. 371, 583–584 (2014).
Park, D. J. et al. Rare mutations in RINT1 predispose carriers to breast and Lynch syndrome-spectrum cancers. Cancer Discov. 4, 804–815 (2014).
Ramus, S. J. et al. Germline mutations in the BRIP1, BARD1, PALB2, and NBN genes in women with ovarian cancer. J. Natl Cancer Inst. 107, djv214 (2015).
Song, H. et al. Contribution of germline mutations in the RAD51B, RAD51C, and RAD51D genes to ovarian cancer in the population. J. Clin. Oncol. 33, 2901–2907 (2015).
Norquist, B. M. et al. Inherited mutations in women with ovarian carcinoma. JAMA Oncol. 2, 482–490 (2016).
Baysal, B. E. et al. Analysis of CHEK2 gene for ovarian cancer susceptibility. Gynecol. Oncol. 95, 62–69 (2004).
Thompson, D. et al. Cancer risks and mortality in heterozygous ATM mutation carriers. J. Natl Cancer Inst. 97, 813–822 (2005).
Johns, L. E. & Houlston, R. S. A systematic review and meta-analysis of familial colorectal cancer risk. Am. J. Gastroenterol. 96, 2992–3003 (2001).
Ma, X., Zhang, B. & Zheng, W. Genetic variants associated with colorectal cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence. Gut 63, 326–336 (2014).
Grant, R. C. et al. Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer. Gastroenterology 148, 556–564 (2015).
Helgason, H. et al. Loss-of-function variants in ATM confer risk of gastric cancer. Nat. Genet. 47, 906–910 (2015).
Naslund-Koch, C., Nordestgaard, B. G. & Bojesen, S. E. Increased risk for other cancers in addition to breast cancer for CHEK2*1100delC heterozygotes estimated from the Copenhagen general population study. J. Clin. Oncol. http://dx.doi.org/10.1200/JCO.2015.63.3594 (2016).
Roberts, N. J. et al. ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov. 2, 41–46 (2012).
Zhen, D. B. et al. BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. 17, 569–577 (2015).
Howlader, N. et al. SEER cancer statistics review, 1975–2012. National Cancer Institute http://seer.cancer.gov/csr/1975_2012/ (2015).
CHEK2 Breast Cancer Case–Control Consortium. CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am. J. Hum. Genet. 74, 1175–1182 (2004).
Antoniou, A. C. et al. Breast-cancer risk in families with mutations in PALB2. N. Engl. J. Med. 371, 497–506 (2014).
Southey, M. C. et al. A PALB2 mutation associated with high risk of breast cancer. Breast Cancer Res. 12, R109 (2010).
Bernstein, J. L. et al. Population-based estimates of breast cancer risks associated with ATM gene variants c.7271T>G and c.1066-6T>G (IVS10-6T>G) from the Breast Cancer Family Registry. Hum. Mutat. 27, 1122–1128 (2006).
Huijts, P. E. et al. CHEK2*1100delC homozygosity in the Netherlands — prevalence and risk of breast and lung cancer. Eur. J. Hum. Genet. 22, 46–51 (2014).
Adank, M. A. et al. CHEK2*1100delC homozygosity is associated with a high breast cancer risk in women. J. Med. Genet. 48, 860–863 (2011).
Shaag, A. et al. Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population. Hum. Mol. Genet. 14, 555–563 (2005).
Han, F. F., Guo, C. L. & Liu, L. H. The effect of CHEK2 variant I157T on cancer susceptibility: evidence from a meta-analysis. DNA Cell Biol. 32, 329–335 (2013).
Adank, M. A. et al. Excess breast cancer risk in first degree relatives of CHEK2*1100delC positive familial breast cancer cases. Eur. J. Cancer 49, 1993–1999 (2013).
Mainiero, M. B. et al. ACR appropriateness criteria breast cancer screening. J. Am. Coll. Radiol 10, 11–14 (2013).
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis, version 1. http://www.nccn.org/professionals/physician_gls/pdf/breast-screening.pdf (2015).
National Institute for Health and Care Excellence. Familial breast cancer: classification, care, and managing breast cancer and related risks in people with a family history of breast cancer. http://www.nice.org.uk/guidance/CG164 (2013).
Warner, E. et al. Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer. Ann. Intern. Med. 148, 671–679 (2008).
Warner, E. et al. Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. J. Clin. Oncol. 29, 1664–1669 (2011).
Thomssen, C. & Harbeck, N. Update 2010 of the German AGO Recommendations for the Diagnosis and Treatment of Early and Metastatic Breast Cancer — chapter B: prevention, early detection, lifestyle, premalignant lesions, DCIS, recurrent and metastatic breast cancer. Breast Care (Basel) 5, 345–351 (2010).
Saadatmand, S. et al. Survival benefit in women with BRCA1 mutation or familial risk in the MRI screening study (MRISC). Int. J. Cancer 137, 1729–1738 (2015).
Heijnsdijk, E. A. et al. Differences in natural history between breast cancers in BRCA1 and BRCA2 mutation carriers and effects of MRI screening-MRISC, MARIBS, and Canadian studies combined. Cancer Epidemiol. Biomarkers Prev. 21, 1458–1468 (2012).
Saslow, D. et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J. Clin. 57, 75–89 (2007).
Quante, A. S. et al. Practical problems with clinical guidelines for breast cancer prevention based on remaining lifetime risk. J. Natl Cancer Inst. 107, djv124 (2015).
King, T. A. et al. Lobular carcinoma in situ: a 29-year longitudinal experience evaluating clinicopathologic features and breast cancer risk. J. Clin. Oncol. 33, 3945–3952 (2015).
Fisher, B. et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl Cancer Inst. 90, 1371–1388 (1998).
Coopey, S. B. et al. The role of chemoprevention in modifying the risk of breast cancer in women with atypical breast lesions. Breast Cancer Res. Treat. 136, 627–633 (2012).
Concannon, P. et al. Variants in the ATM gene associated with a reduced risk of contralateral breast cancer. Cancer Res. 68, 6486–6491 (2008).
Bernstein, J.L. et al. Radiation exposure, the ATM Gene, and contralateral breast cancer in the women's environmental cancer and radiation epidemiology study. J Natl Cancer Inst 102, 475–83 (2010).
Weischer, M. et al. CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer. J. Clin. Oncol. 30, 4308–4316 (2012).
Jervis, S. et al. Ovarian cancer familial relative risks by tumour subtypes and by known ovarian cancer genetic susceptibility variants. J. Med. Genet. 51, 108–113 (2014).
Antoniou, A. et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am. J. Hum. Genet. 72, 1117–1130 (2003).
Jacobs, I. J. et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet 387, 945–956 (2016).
Liang, J. et al. APC polymorphisms and the risk of colorectal neoplasia: a HuGE review and meta-analysis. Am. J. Epidemiol. 177, 1169–1179 (2013).
Zhang, G., Zeng, Y., Liu, Z. & Wei, W. Significant association between Nijmegen breakage syndrome 1 657del5 polymorphism and breast cancer risk. Tumour Biol. 34, 2753–2757 (2013).
Acknowledgements
The authors wish to acknowledge Dr Emily Sonnenblick for critical review and comments on the breast cancer screening component of this analysis.
Author information
Authors and Affiliations
Contributions
N.T., S.M.D. and M.E.R. researched the data and wrote the article. All authors made a substantial contribution to discussion of the content for the article, and reviewed and edited the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
M.E.R. and J.G. receive research support from Myriad Genetics. The other authors declare no competing interests.
Supplementary information
Supplementary Table S1 (table)
Results of panel testing (PDF 206 kb)
Supplementary Table S2 (table)
Impact of variation in RR with age on cumulative risk estimates (PDF 196 kb)
Rights and permissions
About this article
Cite this article
Tung, N., Domchek, S., Stadler, Z. et al. Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nat Rev Clin Oncol 13, 581–588 (2016). https://doi.org/10.1038/nrclinonc.2016.90
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2016.90
This article is cited by
-
Germline mutations of homologous recombination genes and clinical outcomes in pancreatic cancer: a multicenter study in Taiwan
Journal of Biomedical Science (2024)
-
Comprehensive genomic profiling of breast cancers characterizes germline-somatic mutation interactions mediating therapeutic vulnerabilities
Cell Discovery (2023)
-
Female sexual function evaluation and intraoperative vaginal reconstruction in bladder cancer
World Journal of Urology (2023)
-
Psychological and health behaviour outcomes following multi-gene panel testing for hereditary breast and ovarian cancer risk: a mini-review of the literature
Hereditary Cancer in Clinical Practice (2022)
-
Apparent regional differences in the spectrum of BARD1 pathogenic variants in Spanish population and importance of copy number variants
Scientific Reports (2022)